Pyxis Oncology, Inc. (PYXS): Total Assets
$91.52M
As of 2025-12-31
$54.92M
As of 2026-06-30
-24.3%
3-year compound annual growth
+55.2%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $91.52M | -41.8% | 2026-03-23, Balance as of period end |
| 2024-12-31 | $157.18M | -9.5% | 2026-03-23, Balance as of period end |
| 2023-12-31 | $173.73M | -17.8% | 2025-03-18, Balance as of period end |
| 2022-12-31 | $211.38M | -24.5% | 2024-03-21, Balance as of period end |
| 2021-12-31 | $280.02M | n/m | 2023-03-22, Balance as of period end |
| 2020-12-31 | $10.15M | n/a | 2022-03-29, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $91.52M | -41.8% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $6.96M | -12.2% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $94.62M | -28.2% |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | $50.24M | +36.3% |
| Palatin Technologies Inc (PTN) | 2026-06-30 | $8.52M | +160.9% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $277.17M | +70.2% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $224.95M | +195.8% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $21.44M | -9.2% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $141.31M | -19.5% |
Compare PYXS, CVSI, ABUS, IRD side by side · Screen every company in Pharmaceutical Preparations ↗